# Do Longevity Drugs Have Additive Benefits? | Brian Kennedy, Ph.D.

**Channel:** Peter Attia MD
**Upload Date:** 2025-08-08
**URL:** https://www.youtube.com/watch?v=BTMFjyh9v_o
**Duration:** 9 minutes

## Description

Get An Introductory Guide to Longevity and my weekly newsletter here (free): https://bit.ly/44DqWgI
Watch the full episode: https://youtu.be/7yNvz_0Q1eQ
Become a member to receive exclusive content: https://bit.ly/46Op460

This clip is from episode  #357 ‒ A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions | Brian Kennedy, Ph.D.

In this clip, they discuss:

- Designing a Longevity Drug Study – Hypothetical six-arm trial testing metformin, rapamycin, SGLT2 inhibitors, and GLP-1 agonists in metabolically healthy middle-aged people
- Mechanisms of Action Questioned – The conversation explores whether these drugs benefit healthy individuals or only those with metabolic irregularities
- Lean Muscle Mass Concerns – Concerns about potential loss of lean muscle mass with some longevity drugs
- What Makes a Drug Truly Anti-Aging? – Whether correcting metabolic issues equates to slowing aging, or merely normalizing lifespan
- Additive vs. Confounding Effects – Combining drugs is likened to mixing 20 paint colors—more likely to create unpredictable outcomes than additive ones

--------
About:

The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 90 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.

Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan. 

Learn more: https://peterattiamd.com

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: https://peterattiamd.com/terms-of-use/

## AI Summary

Here's my analysis of this clip from The Drive podcast with Brian Kennedy:

**1. Executive Summary**:
This discussion focuses on the comparative effectiveness of various longevity drugs and their potential additive benefits. Dr. Kennedy and Dr. Attia explore the efficacy of medications like metformin, rapamycin, SGLT2 inhibitors, and GLP-1 agonists in healthy individuals. They particularly examine whether these interventions truly slow aging or merely normalize longevity in less healthy populations.

**2. Key Medical/Scientific Points**:
- Discussion of comparative effectiveness between metformin, rapamycin, SGLT2 inhibitors, and GLP-1 agonists [00:00:00]
- Analysis of hemoglobin A1C levels and their correlation with mortality (5.0 vs 5.4) [00:04:23]
- Observation that combining multiple interventions often leads to cancellation rather than additive effects [00:06:24]

**3. Health Optimization Tips**:
Universal Recommendations:
- Focus on optimizing glucose homeostasis through diet, sleep, and exercise [00:01:52]
- Try one or two interventions at a time rather than multiple simultaneous changes [00:06:24]

Risk/Benefit Considerations:
- GLP-1 agonists may cause concerning muscle mass loss [00:05:17]
- Higher lean muscle mass with slightly more fat may be preferable to low muscle mass [00:05:35]

**4. Supplements & Medications**:
Medications discussed:
- Metformin (skepticism about effectiveness) [00:00:25]
- Rapamycin [00:00:25]
- SGLT2 inhibitors [00:00:25]
- GLP-1 agonists [00:00:25]

**9. Notable Quotes**:
"If you're doing 10 things, you don't have any idea what's working and what's not working and whether things might be impairing each other." [00:06:47]

**10. Follow-up Questions**:
1. What are the specific mechanisms by which these drugs might work in metabolically healthy individuals?
2. How can we better measure the impact of combined interventions?
3. What is the optimal protocol for testing individual interventions while controlling for other variables?

Note: The transcript ends before completing all discussion points, so some sections (5-8) cannot be fully analyzed from the provided excerpt.
